Hospitals, drug companies and oncology patients are in an uneasy financial dance

When it comes to drugs, cure pricing and trends, hospitals, the pharmaceutical sector and patients–particularly those battling cancer–are in a constantly shifting and often uneasy financial position.

In a report conducted on behalf of the Community Oncology Alliance by the Berkeley Research Group, the COA noted that disproportionate share hospitals have seen their 340B revenue grow from 12 percent of hospital outpatient revenues in 2003 to almost 40 percent in 2013 (340B is an outpatient-based program).

When all 340B participant hospitals are factored in, the percentage of 340B-related revenue increases to 47 percent for 2013. The report did note that the Affordable Care Act has expanded 340B eligibility significantly in recent years, increasing from 430 in 2010 to 1,546 in 2013.

Read Full Article Here >>